» Articles » PMID: 30597997

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Jan 2
PMID 30597997
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth, but in most cancers it is overexpressed and associated with treatment-resistance and lethal outcomes. Over 40 years of research and drug development efforts did not yield a clinically useful Myc inhibitor. Drugging the "undruggable" is problematic, as Myc inactivation may negatively impact its physiological functions. Moreover, Myc is a disordered protein that lacks effective binding pockets on its surface. It is well established that the Myc function is dependent on dimerization with its obligate partner, Max (Myc associated factor X), which together form a functional DNA-binding domain to activate genomic targets. Herein, we provide an overview of the knowledge accumulated to date on Myc regulation and function, its critical role in cancer, and summarize various strategies that are employed to tackle Myc-driven malignant transformation. We focus on important structure-function relationships of Myc with its interactome, elaborating structural determinants of Myc-Max dimer formation and DNA recognition exploited for therapeutic inhibition. Chronological development of small-molecule Myc-Max prototype inhibitors and corresponding binding sites are comprehensively reviewed and particular emphasis is placed on modern computational drug design methods. On the outlook, technological advancements may soon provide the so long-awaited Myc-Max clinical candidate.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways.

Seres M, Spacayova K, Sulova Z, Spaldova J, Breier A, Pavlikova L Cancers (Basel). 2025; 17(2).

PMID: 39858030 PMC: 11763799. DOI: 10.3390/cancers17020248.


Identification of MYC and STAT3 for early diagnosis based on the long noncoding RNA-mRNA network and bioinformatics in colorectal cancer.

Yao K, Fan H, Yang T, Yang C, Wang G, Li X Front Immunol. 2025; 15():1497919.

PMID: 39830506 PMC: 11739134. DOI: 10.3389/fimmu.2024.1497919.


Study of the Anti-MYC Potential of Lanostane-Type Triterpenes.

Oliveira J, Negreiro J, Nunes F, Barbosa F, Mafezoli J, Mattos M ACS Omega. 2025; 9(51):50844-50858.

PMID: 39741863 PMC: 11683602. DOI: 10.1021/acsomega.4c10201.


New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.

Nada H, Choi Y, Kim S, Jeong K, Meanwell N, Lee K Signal Transduct Target Ther. 2024; 9(1):341.

PMID: 39638817 PMC: 11621763. DOI: 10.1038/s41392-024-02036-3.


References
1.
Makela T, Koskinen P, Vastrik I, Alitalo K . Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science. 1992; 256(5055):373-7. DOI: 10.1126/science.256.5055.373. View

2.
Itzen F, Greifenberg A, Bosken C, Geyer M . Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 2014; 42(12):7577-90. PMC: 4081074. DOI: 10.1093/nar/gku449. View

3.
Kiessling A, Wiesinger R, Sperl B, Berg T . Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem. 2007; 2(5):627-30. DOI: 10.1002/cmdc.200600294. View

4.
Han X, Li C, Mosher M, Rider K, Zhou P, Crawford R . Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates. Bioorg Med Chem. 2009; 17(4):1671-80. PMC: 2978248. DOI: 10.1016/j.bmc.2008.12.056. View

5.
Yuza Y, Kawakami M, Takagi K, Yamazaki Y, Urashima M . Max protein expression is associated with survival of children with lymphoblastic lymphoma. Pediatr Int. 2000; 41(6):637-40. DOI: 10.1046/j.1442-200x.1999.01140.x. View